Phase II trial of OGX-011 in combination with docetaxel in metastatic breast cancer

Clinical Cancer Research

Volumn 15, Issue 2, 2009, Pages 708-713

  Chia, Stephen ^a,f   Dent, Susan ^b   Ellard, Susan ^a   Ellis, Peter M ^c   Vandenberg, Ted ^d   Gelmon, Karen ^a   Powers, Jean ^e   Walsh, Wendy ^e   Seymour, Lesley ^e   Eisenhauer, Elizabeth A ^e  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b OTTAWA REGIONAL CANCER CENTRE   (Canada)

^c JURAVINSKI CANCER CENTRE   (Canada)

^d LONDON REGIONAL CANCER PROGRAM   (Canada)

^e Queen's Cancer Research Institute   (Canada)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLUSTERIN; DOCETAXEL; OGX 011;

ADULT; AGED; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BLADDER INFECTION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EMBOLISM; FATIGUE; FEBRILE NEUTROPENIA; FRACTURE; GRANULOCYTOPENIA; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; ILEUS; INFECTION; INTESTINE OBSTRUCTION; LEUKOPENIA; LIMB PAIN; LOADING DRUG DOSE; LUNG INFECTION; LYMPHOCYTOPENIA; MENSTRUAL IRREGULARITY; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NECK PAIN; NEUTROPENIA; NONHEMATOLOGIC TOXICITY; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RIGOR; SIDE EFFECT; SYNCOPE; THROMBOCYTOPENIA; THROMBOSIS; THROMBUS; TOXICITY; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BREAST NEOPLASMS; CLUSTERIN; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; OLIGONUCLEOTIDES, ANTISENSE; TAXOIDS; THIONUCLEOTIDES; TREATMENT OUTCOME;

EID: 59449084118     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1159     Document Type: Article

References (25)

1. Parkin DM, Bray Fl, Ferlay F, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Giordano SH, Buzdar AU, Smith TL, et al. Is breast cancer survival improving? Trends in survival for patients with recurrent breast cancer diagnosed from 1974 through 2000. Cancer 2004;100:44-52.
3. Arveux P, Grosclaude P, Reyrat E, et al. Breast cancer survival in France: a relative survival analysis based on 68,449 cases treated in the 20 French comprehensive cancer centres between 1980 and 1999. Proc Am Soc Clin Oncol 2003;22:3437a.
4. Chia S, Speers CH, D'yachkova Y, et al. The impact of new chemotherapeutics and hormonal agents on survival in a population based cohort of women with metastatic breast cancer. Cancer 2007;110:973-9.
5. Ringel I, Horwitz SB. Studies with RP56976 (Taxo-tere): a semi-synthetic analogue of Taxol. J Natl Cancer Inst 1991;83:288-91.
6. Jones SE, Erban B, Overmoyer GT, et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005;23:5542-51.
7. Redondo M, Villar E, Torres-Munoz J, et al. Overex-pression of clusterin in human breast carcinoma. Am J Pathol 2000;157:393-9.
8. Zhang S, Zhang D, Zhu Y, et al. Clusterin expression and univariate analysis of overall survival in human breast cancer. Technol Cancer Res Treat 2006;5:573-8.
9. Kruger S, Ola V, Fischer D, et al. Prognostic significance of clusterin immunoreactivity in breast cancer. Neoplasma 2007;54:46-50.
10. So A, Sinnermann S, Huntsman D, et al. Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivo. Mol CancerTher 2005;4:1837-49.
11. Biroccio A, D'Angelo C, Jansen B, et al. Antisense clusterin oligonucleotides increases the response of HER-2 gene amplified breast cancer cells to trastuzumab. J Cell Physiol 2005;204:463-9.
12. Warri AM, Huovinen RL, Laine AM, et al. Apoptosis in toremifene induced growth inhibition of human breast cancer cells in vivo and in vitro. J Natl Cancer Inst 1993;85:1412-8.
13. Zellweger T, Miyake H, Cooper S, et al. Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2′-O-(2-methoxy) ethyl chemistry. J Pharmacol Exp Ther 2001;298:934-40.
14. Chi KN, Eisenhauer E, Fazli L, et al. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst 2005;97:1287-96.
15. Chi KN, Siu LL, Hirte H et al. A phase I study of OGX-011, a 2′-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clin Cancer Res 2008;14:833-9.
16. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
17. Simon RM. Optimal two-stage design for phase II clinical trials. Control Clin Trials 1989;10:1.
18. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
19. Valero V, Holmes FA, Walters RS, et al. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline re-sistant metastatic breast cancer. J Clin Oncol 1995;13:2886-94.
20. Ravdin PM, Burris HA, Cook G, et al. Phase II trial of docetaxel in advanced anthracycline resistant or anthracenedione-resistant breast cancer. J Clin Oncol 1995;13:2879-85.
21. Chan S, Friedrichs K, Noel D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999;17:2341-54.
22. O'Brien ME, Leonard RC, Barrett-Lee PJ, et al. Docetaxel in thecommunity setting: an analysis of 377 breast cancer patients treated with docetaxel in the UK-UK Study Group. Ann Oncol 1999;10:205-10.
23. Harvey V, Mouridsen H, SemiglazovV, et al. Phase III trial comparing three doses of docetaxel for second line treatment of advanced breast cancer. J Clin Oncol 2006;24:4963-70.
24. Waters JS, Webb A, Cunningham D, et al. Phase I clinical and pharmacokinetic study of bcl-2 anti-sense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 2000;18: 1812-23.
25. Nemunaitis J, Holmlund JT, Kraynak M, et al. Phase I evaluation of ISIS 3521, an antisense oligo-deoxynucleotide to protein kinase C-a, in patients with advanced cancer. J Clin Oncol 1999; 17:3586-95.